CTLA4 and melanoma: By comparison, although clinical outcomes for patients with advanced melanomas have historically been poor5, advances in adjuvant checkpoint immunotherapies, and especially combination (anti-PD1 + anti-CTLA4) immunotherapies, have demonstrated significant patient survival benefits6, to the extent that melanoma has become a model cancer for understanding immunotherapy responses.